Effects of MICA Expression on the Prognosis of Advanced Non-Small Cell Lung Cancer and the Efficacy of CIK Therapy

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Chen, Yu ^a,b   Lin, Gen ^a,b   Guo, Zeng qing ^a,b,c   Zhou, Zhi feng ^a,b   He, Zhi yong ^a,b   Ye, Yun bin ^a,b  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b Fujian Key Laboratory of Translational Cancer Medicine   (China)

^c Fujian Provincial Key Laboratory of Theoretical and Computational Chemistry   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; PEMETREXED; PLATINUM DERIVATIVE;

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; ARTICLE; AUTOTRANSPLANTATION; CANCER PROGNOSIS; CANCER STAGING; CANCER TISSUE; CELL MEMBRANE; CELL THERAPY; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; CYTOPLASM; ECOG SCORE; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MHC CLASS I CHAIN RELATED GENE A; OUTCOME ASSESSMENT; OVERALL SURVIVAL; SCORING SYSTEM; SEX RATIO; THERAPY EFFECT; TREATMENT DURATION;

CARCINOMA, NON-SMALL-CELL LUNG; CELL COUNT; CYTOKINE-INDUCED KILLER CELLS; FEMALE; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; PHENOTYPE; PROGNOSIS; TREATMENT OUTCOME;

EID: 84880741675     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069044     Document Type: Article

References (34)

1. Jemal A, Bray F, (2011) Center MM, Ferlay J, Ward E, et al (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Stroncek D, Berlyne D, Fox B, Gee A, Heimfeld S, et al. (2010) Developments in clinical cell therapy. Cytotherapy 12: 425-428.
3. Kakimi K, Nakajima J, Wada H, (2009) Active specific immunotherapy and cell-transfer therapy for the treatment of non-small cell lung cancer. Lung Cancer 65: 1-8.
4. Hontscha C, Borck Y, Zhou H, Messmer D, Schmidt-Wolf IG, (2011) Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol 137: 305-310.
5. Dougan M, Dranoff G, (2009) Immune therapy for cancer. Annu Rev Immunol 27: 83-117.
6. Dunn GP, Old LJ, Schreiber RD, (2004) The three Es of cancer immunoediting. Annu Rev Immunol 22: 329-360.
7. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, et al. (1999) Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285: 727-729.
8. Salih HR, Antropius H, Gieseke F, Lutz SZ, Kanz L, et al. (2003) Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 102: 1389-1396.
9. Groh V, Steinle A, Bauer S, Spies T, (1998) Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. Science 279: 1737-1740.
10. Gleimer M, Parham P, (2003) Stress management: MHC class I and class I-like molecules as reporters of cellular stress. Immunity 19: 469-477.
11. Zamai L, Ponti C, Mirandola P, Gobbi G, Papa S, et al. (2007) NK cells and cancer. J Immunol 178: 4011-4016.
12. Pardoll DM, (2001) Immunology. Stress, NK receptors, and immune surveillance. Science 294: 534-536.
13. Hayakawa Y, Kelly JM, Westwood JA, Darcy PK, Diefenbach A, et al. (2002) Cutting edge: tumor rejection mediated by NKG2D receptor-ligand interaction is dependent upon perforin. J Immunol 169: 5377-5381.
14. Friese MA, Platten M, Lutz SZ, Naumann U, Aulwurm S, et al. (2003) MICA/NKG2D-mediated immunogene therapy of experimental gliomas. Cancer Res 63: 8996-9006.
15. Salih HR, Rammensee HG, Steinle A, (2002) Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol 169: 4098-4102.
16. Shi M, Zhang B, Tang ZR, Lei ZY, Wang HF, et al. (2004) Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma. World J Gastroenterol 10: 1146-1151.
17. Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL, (1991) Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 174: 139-149.
18. Schmidt-Wolf IG, Lefterova P, Mehta BA, Fernandez LP, Huhn D, et al. (1993) Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol 21: 1673-1679.
19. Verneris MR, Karami M, Baker J, Jayaswal A, Negrin RS, (2004) Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood 103: 3065-3072.
20. Huang B, Sikorski R, Sampath P, Thorne SH, (2011) Modulation of NKG2D-ligand cell surface expression enhances immune cell therapy of cancer. J Immunother 34: 289-296.
21. Guerra N, Tan YX, Joncker NT, Choy A, Gallardo F, et al. (2008) NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 28: 571-580.
22. Watson NF, Spendlove I, Madjd Z, McGilvray R, Green AR, et al. (2006) Expression of the stress-related MHC class I chain-related protein MICA is an indicator of good prognosis in colorectal cancer patients. Int J Cancer 118: 1445-1452.
23. Madjd Z, Spendlove I, Moss R, Bevin S, Pinder SE, et al. (2007) Upregulation of MICA on high-grade invasive operable breast carcinoma. Cancer Immun 7: 17.
24. Li K, Mandai M, Hamanishi J, Matsumura N, Suzuki A, et al. (2009) Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis. Cancer Immunol Immunother 58: 641-652.
25. McCarty KS Jr, Miller LS, Cox EB, Konrath J, McCarty KS, (1985) Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 109: 716-721.
26. Busche A, Goldmann T, Naumann U, Steinle A, Brandau S, (2006) Natural killer cell-mediated rejection of experimental human lung cancer by genetic overexpression of major histocompatibility complex class I chain-related gene A. Hum Gene Ther. 17: 135-146.
27. Raulet DH, (2003) Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 3: 781-790.
28. Lanier LL, (2001) A renaissance for the tumor immunosurveillance hypothesis. Nat Med 7: 1178-1180.
29. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH, (2001) Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 413: 165-171.
30. Xiao P, Xue L, Che LH, Peng JJ, Wu HX, et al. (2008) Expression and roles of MICA in human osteosarcoma. Histopathology 52: 640-642.
31. Groh V, Wu J, Yee C, Spies T, (2002) Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419: 734-738.
32. Wang Y, Dai H, Li H, Lv H, Wang T, et al. (2011) Growth of human colorectal cancer SW1116 cells is inhibited by cytokine-induced killer cells. Clin Dev Immunol 2011: 621414.
33. Helms MW, Prescher JA, Cao YA, Schaffert S, Contag CH, (2010) IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy. Cancer Immunol Immunother 59: 1325-1334.
34. Mesiano G, Todorovic M, Gammaitoni L, Leuci V, Giraudo DL, et al. (2012) Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. Expert Opin Biol Ther 12: 673-684.